JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

KemPharm Inc

Closed

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

33M

-3.1M

Sales

8.4M

20M

Profit margin

-15.19

Employees

59

EBITDA

11M

-5.4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+115.23% upside

Dividends

By Dow Jones

Next Earnings

12 Aug 2025

Market Stats

By TradingEconomics

Market Cap

217M

641M

Previous open

0

Previous close

0

KemPharm Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Feb 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million

5 Aug 2024, 11:25 UTC

Major Market Movers

Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol

Peer Comparison

Price change

KemPharm Inc Forecast

Price Target

By TipRanks

115.23% upside

12 Months Forecast

Average 24.17 USD  115.23%

High 29 USD

Low 19 USD

Based on 7 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$